Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis

期刊论文
出版模式：

开放获取
发表日期：

2024年9月9日

查看全文

Xiansheng Yang,
Chang Liu,
Zheng Li,
Juncai Wen,
Jinfu He,
Yunxin Lu,
Quanxing Liao,
Tian Wang,
Hongsheng Tang,
Xianzi Yang,
Lisi Zeng

摘要

Background

Gastric cancer (GC), a prevalent malignant tumor which is a leading cause of death from malignancy around the world. Peritoneal metastasis accounts for the major cause of mortality in patients with GC. Despite hyperthermia intraperitoneal chemotherapy (HIPEC) improves the therapeutic effect of GC, it’s equivocal about the mechanism under HIPEC.

Methods

MiR-183-5p expression was sifted from miRNA chip and detected in both GC patients and cell lines by qRT-PCR. Gene interference and rescue experiments were performed to identified biological function in vitro and vivo. Next, we affirmed PPP2CA as targeted of miR-183-5p by dual luciferase reporter assay. Finally, the potential relationship between HIPEC and miR-183-5p was explored.

Results

MiR-183-5p is up-regulated in GC and associated with advanced stage and poor prognosis. MiR-183-5p accelerate GC migration in vitro which is influenced by miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin Axis. HIPEC exerts migration inhibition via attenuating miR-183-5p expression.

Conclusion

MiR-183-5p can be used as a potential HIPEC biomarker in patients with CC.